Evidence map›Paper›PMID 37605081›Full record

ArticleAnnals of surgical oncology2023

Effect of Delayed Oncoplastic Reduction Mammoplasty on Radiation Treatment Delay Following Breast-Conserving Surgery for Breast Cancer.

Carolina E Fasola, Hadley J Sharp, Nicholas W Clavin, Wei Sha, Courtney R Schepel, Sally J Trufan, Elaina Graham, Anna Hecksher, Richard L White, Lejla Hadzikadic-Gusic

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Carolina E FasolaDepartment of Radiation Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Hadley J SharpDepartment of Radiation Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Nicholas W ClavinDivision of Plastic and Reconstructive Surgery, Atrium Health, Charlotte, NC, USA.
Wei ShaDepartment of Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Courtney R SchepelClinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Sally J TrufanDepartment of Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Elaina GrahamDivision of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Anna HecksherClinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Richard L WhiteDivision of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Lejla Hadzikadic-GusicDivision of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. lejla.hadzikadic-gusic@atriumhealth.org.
Levine Cancer Institute · USAtrium Medical Cente · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe purpose of this study was to evaluate the delay in initiating adjuvant radiation therapy (RT) after breast-conserving surgery (BCS) in patients with early-stage breast cancer who underwent oncoplastic reduction mammoplasty (ORM) following BCS compared with a matched cohort of patients who did not undergo ORM between BCS and RT.

methodsMedical records of 112 women (56 ORMs and 56 matched non-ORMs) with carcinoma in situ or early-stage breast cancer treated with BCS were reviewed. ORM was performed in a delayed manner following BCS, allowing confirmation of negative surgical margins. Time to RT was defined as time from last oncologic surgery to start of RT.

resultsThe median follow-up time was 6.8 years for the ORM cohort and 6.7 years for the control non-ORM cohort. Patients who underwent ORM following BCS experienced a significant delay in initiating RT (>8 weeks) than matched patients not undergoing ORM (66% vs. 34%; p < 0.001). Wound complications occurred in 44.6% (n = 25) of patients in the ORM cohort, which were mostly minor, including delayed wound healing and/or infection (39%). There was no significant difference in local recurrence between patients in the non-ORM and ORM cohorts (p = 0.32).

conclusionsThis study demonstrates that ORM following BCS has the potential to delay RT >8 weeks, largely as a result of increased risk of wound complications; however, this delay did not impact local control. ORM can be safely considered for appropriately selected patients with breast cancer.

Indexed as

Breast NeoplasmsMammaplastyFemaleHumansMargins of ExcisionMastectomy, SegmentalNeoplasm Recurrence, LocalRetrospective StudiesBreast cancerBreast-conserving therapyOncoplastic reconstructionRadiation delay

Identifiers

PMID37605081
OpenAlexW4386026109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.